• BRCA2 and Nascent Strand Maturation in the Presence of Olapa

  2026-05-20

  A recent study reveals that BRCA2 is essential for the maturation of nascent DNA strands when PARP inhibitors like Olaparib impede DNA replication. These insights clarify the interplay between DNA repair pathways and inform the design of DNA damage response and tumor radiosensitization studies.

• Gepotidacin (GSK2140944): Transformative Tools for Antibacte

  2026-05-20

  Gepotidacin (GSK2140944) empowers researchers to dissect bacterial DNA replication inhibition with precision, enabling robust modeling of antibiotic resistance and novel antibacterial workflows. This guide details protocol enhancements, troubleshooting strategies, and experimental insights tailored to maximize the unique dual-targeting potential of Gepotidacin.

• Gepotidacin (GSK2140944): Applied Protocols in Antibacterial

  2026-05-19

  Gepotidacin (GSK2140944), a first-in-class triazaacenaphthylene antibiotic, transforms antibacterial research with its unique mechanism targeting DNA gyrase and topoisomerase IV—even in fluoroquinolone-resistant strains. This guide delivers actionable protocols, troubleshooting strategies, and insights drawn from recent molecular advances to empower cutting-edge antibiotic resistance research.

• Vincristine Sulfate (A1765) for Reliable Cancer Research Wor

  2026-05-19

  This article delivers scenario-driven guidance for scientists employing Vincristine sulfate (SKU A1765) in cell viability, cytotoxicity, and proliferation assays. We address real laboratory challenges—such as solubility, reproducibility, and data interpretation—by grounding recommendations in primary product data and peer-reviewed literature. Researchers will find validated protocols and clear rationales for selecting Vincristine sulfate in demanding oncology and cell biology workflows.

• Microbiota–Tryptophan–AhR Axis in Ulcerative Colitis Repair

  2026-05-18

  Li et al. (2026) establish that Huangqin decoction (HQD) repairs ulcerative colitis by modulating the gut microbiome to enhance tryptophan metabolism and activate the aryl hydrocarbon receptor (AhR), thereby promoting intestinal stem cell differentiation and mucosal healing. This work clarifies a novel mechanistic axis, providing a foundation for targeted therapeutic strategies in inflammatory bowel disease.

• WAY-100635 in Neuroscience: Precision Tools for 5-HT1A Antag

  2026-05-18

  WAY-100635, a selective 5-HT1A antagonist, transforms serotonin receptor antagonist research with unrivaled specificity and reproducibility. This guide decodes optimized workflows, advanced applications, and troubleshooting strategies, turning complex neuropharmacology into actionable protocols.

• Amyloid Beta-Peptide (1-40) (human): Optimized Experimental

  2026-05-17

  Amyloid Beta-Peptide (1-40) (human) from APExBIO empowers cutting-edge Alzheimer's disease research through its proven fidelity in modeling amyloid fibril formation and neurotoxicity. This article distills advanced workflows, troubleshooting tactics, and the latest mechanistic insights to help researchers achieve reproducible, translational results.

• RG7388 and the Translational Frontier in Precision p53 Activ

  2026-05-16

  This thought-leadership article explores the mechanistic and translational impact of RG7388, a next-generation MDM2 antagonist, on p53 pathway activation and cancer cell apoptosis. Integrating recent evidence on MDM1 as a predictive biomarker for chemoradiotherapy sensitivity, we provide strategic guidance for researchers seeking to overcome resistance and optimize preclinical and clinical study designs. Actionable protocol parameters and a critical appraisal of the competitive landscape position RG7388 as a benchmark for selective p53 activation in oncology translational workflows.

• Lypressin Acetate: Mechanistic Insights for Translational Pr

  2026-05-15

  Explore how lypressin acetate bridges antidiuretic, vasopressor, and antiviral research. This thought-leadership article synthesizes mechanistic rationale, protocol benchmarks, and strategic guidance for translational scientists, drawing from peer-reviewed evidence and APExBIO’s rigorously validated offering.

• PLAC1 as a Prognostic Biomarker and Target in ccRCC: Evidenc

  2026-05-15

  A recent study identifies placenta-specific protein 1 (PLAC1) as a prognostic biomarker and molecular target in clear cell renal cell carcinoma (ccRCC). High-throughput screening and experimental validation reveal that PLAC1 inhibition can reduce tumor progression, providing a new direction for targeted therapy in ccRCC.

• Practical Use of EDC.HCl (3-(ethyliminomethylideneamino)-N,N

  2026-05-14

  EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride) is a water-soluble carbodiimide reagent designed for efficient amide bond formation in peptide synthesis, bioconjugation, and nucleotide synthesis workflows. It is not suitable for in vivo or clinical applications, and its performance depends on strict adherence to storage and handling protocols.

• AI-Based Disulfidptosis Model Links c-MET to T Cell Exhausti

  2026-05-14

  This study presents an artificial intelligence-driven model to predict immune responses in cancer by leveraging disulfidptosis gene signatures, with a focus on glioma. The research validates c-MET as a key oncogene regulating T cell exhaustion, offering new insights for therapeutic targeting and immune stratification.

• Tankyrase 1/2 Inhibition Modulates Hippo Pathway in HCC Cell

  2026-05-13

  Jia et al. (2017) demonstrated that tankyrase 1/2 inhibitors, including G007-LK, suppress hepatocellular carcinoma (HCC) cell growth through modulation of the Hippo pathway, specifically by downregulating YAP activity via stabilization of AMOTL1/2. These findings provide mechanistic insight into cross-talk between tankyrase targets and cancer-critical signaling, supporting the rationale for further translational studies.

• Phosphatase Inhibitor Cocktail 3 (100X in DMSO): Reliable Ph

  2026-05-13

  This scenario-driven guide addresses common laboratory challenges in phosphoprotein analysis, focusing on how Phosphatase Inhibitor Cocktail 3 (100X in DMSO), SKU K1014, ensures reproducible, high-fidelity preservation of protein phosphorylation states. Readers will find evidence-based protocol guidance and practical Q&A rooted in real experimental contexts.

• Gastrin I: Precision Tools for Gastric Acid Secretion Pathwa

  2026-05-12

  Gastrin I (human) delivers unparalleled control and reproducibility for in vitro studies of gastric acid secretion and gastrointestinal physiology. This article reveals advanced experimental workflows, troubleshooting strategies, and key insights for integrating Gastrin I (human) into hiPSC-derived organoid systems and beyond.

14740 records 3/983 page Previous Next 12345 下5页 Last page